|
|
|
Agenda
Day 1 - 4 September
|
09:00 |
Biomarkers Clinical Applications
Chaired by Mathias Uhlén, Professor, KTH Biotechnology |
|
09:05 |
Biomarkers in Early Clinical Oncology Drug Development
Heinz Zwierzina, Professor, Innsbruck Medical University (IMU)
Proteomics has shown to be a potential tool to discriminate between benign and malignant tumour lesions. This technique also holds promise for the monitoring of functional effects of investigational agents and is expected to provide us with new biomarkers for evaluation of response and / or resistance. |
|
09:35 |
Metabolomics Strategy to Identify Tissue Specific Drug Effects
Matej Orešič, Chief Research Scientist, VTT Technical Research Centre
Metabolomics provides an excellent approach to characterize phenotypes and thus to discover new biomarkers of complex physiological conditions. It can complement and augment genomics and proteomics and thus requires a powerful data integration platform to combine different types of information. |
|
10:05 |
Coffee Break and Networking in Exhibition Hall |
|
10:50 |
Signal-Amplifying Biomarkers for the Diagnosis of Invasive Fungal Infections
Markus Kalkum, Assistant Professor, Beckman Research Institute
A novel proteomic methodology that discovers and exploits fungal protease activities as signal amplifying biomarkers for the diagnosis, prognosis and monitoring of invasive fungal infections. |
|
11:20 |
Personalised Cancer Therapy Based on DNA Repair Inhibition
Mark O’Connor, Director of Translational Science, KuDOS Pharmaceuticals
Inhibitors of DNA repair pathways are now in the clinic. Key to successful development is the identification of biomarkers for DNA damage response pathways. How 2D-DiGE proteomics is being used to achieve this will be described. |
|
11:50 |
Lunch and Networking in Exhibition Hall |
|
13:00 |
Poster Viewing |
|
13:45 |
Enabling Tools for Biomarkers Identification
Chaired by Roy Goodacre, Professor of Biological Chemistry, University of Manchester |
|
13:50 |
A Human Protein Atlas
Mathias Uhlén, Professor, KTH Biotechnology
The Human Protein Atlas portal (www.proteinatlas.org) contains 1.2 million high-resolution images corresponding to more than 1500 antibodies towards human proteins. The use of the database as a tool for medical research, in particular for biomarker analysis in various patient cohorts, will be discussed. |
|
14:20 |
Validation of Novel Breast Cancer Biomarkers Arising from Re-Analysis of Publicly Available DNA Microarray Datasets via Tissue Microarray Technology and Automated Quantitative Scoring Models for Immunohistochemistry
William Gallagher, Associate Professor, University College Dublin
The strategy here has been to mine data from transcriptomic screens and subsequent validation of candidate biomarkers on tissue microarrays. Digital slide scanning approaches were employed to facilitate both manual and automated scoring. |
|
14:50 |
Critical Success Factors in the Development and Implementation of Biomarkers in Drug Development
Roger Wiprächtiger, Key Account Manager, QIAGEN
Novel technologies useful in biomarker discovery and development, as well as a case study of the technology implementation capabilities in pharma partnerships, will be described. |
|
15:20 |
Coffee Break and Networking in Exhibition Hall |
|
16:05 |
New Molecular Tools for Ultra-Sensitive Analysis of Biomarkers
Anders Alderborn, Associate Professor, Uppsala University
Proximity ligation is a new technology which permits highly specific analysis of protein biomarkers. The technology, which is now applied for biomarker evaluation, can specifically detect very low amounts of biomolecules in blood and even single copies in situ. |
|
16:35 |
The Way to Safety Biomarkers: Holy Grail of Toxicology
Thomas Herget, Director New Technology Evaluation, Division Chemicals R&D, Merck
Lowering attrition rate during clinical trials is a major goal to reduce drug development expenditures. New technologies addressing protein expression profiling of biomarkers in pre-clinical test systems will help to identify toxic effects of drug candidates earlier. |
|
17:05 |
Statistical Validation of Biomarkers
Huub Hoefsloot, Associate Professor, University of Amsterdam
In –omics data the number of possible markers is much larger then the number of experiments. This type of data structure can easily lead to chance results in biomarker discovery. This presentation will show strategies to find statistically valid biomarkers. |
|
17:35 |
Drinks Reception Compliments of Dionex |
Day 2 - 5 September
|
09:00 |
Biomarkers Profiling and Discovery
Chaired by Salvatore Sechi, Director, Proteomic Program, NIDDK, NIH |
|
09:05 |
Understanding Biological Systems Using Metabolomics and Proteomics
Roy Goodacre, Professor of Biological Chemistry, University of Manchester
An overview of metabolomics and inductive reasoning for turning metabolite data into knowledge will be presented and spatial metabolic fingerprinting and proteomics will also be reported. |
|
09:35 |
Advancing Discovery with Protein Microarrays
Michael Smith, R&D Scientist, Invitrogen Corporation
Protein microarrays have been successfully applied to investigate the circulating antibody profile in several disease states. Invitrogen has developed a high content human protein microarray containing over 8,000 full-length, functional proteins for the discovery of novel and known autoantibody markers associated with cancer and autoimmune disease. |
|
10:05 |
High-Throughput Disease Proteomics Using Recombinant Antibody Microarrays
Christer Wingren, Assistant Professor, Dept. of Immunotechnology, Lund University, Sweden
A state-of-the art recombinant antibody microarray technology platform for high-throughput (disease) proteomics of non-fractionated proteomes has been devised. Based on a non-invasive blood test, the platform can be used to detect potentially diseased-associated serum protein biomarker signatures, providing novel opportunities for biomarker screening and disease diagnostics. |
|
10:35 |
Coffee Break and Networking in Exhibition Hall |
|
11:20 |
Use of Human Plasma Depletion Technology and Antibody Arrays for the Rapid Detection of Biomarkers in Human Serum Samples
Richard Pembrey, Functional Proteomics Segment Manager, Sigma Aldrich
Antibody arrays will be presented as a powerful tool for rapid expression profiling of proteins and that may potentially be applied to biomarker discovery in diseased serum samples. |
|
11:50 |
The Quantitative Nature of Fourier Transform Mass Spectrometry in Biomarker Discovery
Theo Luider, Head of the Laboratories of Neuro-Oncology, Department of Neurology, Erasmus University of Rotterdam
Maldi Fourier transform ion cyclotron resonance mass spectrometry (MALDI FTMS) can be used in gel free, label free approaches to quantify large numbers of natural occurring and tryptic generated peptides in cerebrospinal fluids and laser microdissected tissues. |
|
12:20 |
Lunch and Networking in Exhibition Hall |
|
13:30 |
Poster Viewing |
|
14:15 |
Disease Specific Biomarkers
Chaired by Christer Wingren, Assistant Professor, Dept. of Immunotechnology, Lund University |
|
14:20 |
A Search for a Biomarker for Monitoring and Predicting Diabetes
Salvatore Sechi, Director, Proteomic Program, NIDDK, NIH
The use of new proteomic biomarker for the development of an assay for detecting pre-diabetes and diabetes will be discussed. Several projects mainly involving protein characterization by mass spectrometry and proteomic profiling of plasma samples will also be described. |
|
14:50 |
Chemical Proteomics for the Identification of Vascular Markers of Disease
Jascha-N. Rybak, Research Scientist, Group of Prof. Dario Neri, ETH Zurich
The group uses vascular biotinylation procedures, followed by a mass-spectrometry-based comparative proteomic analysis of biotinylated proteins, to identify novel markers of pathology, which are easily accessible from the bloodstream and thus ideally suited as targets for antibody-based drug delivery applications. |
|
15:20 |
Poster Award and Coffee Break |
|
15:50 |
A Serum Efficiacy Biomarker for Clinical Trials: Measuring Tumour Cell Apoptosis and Necrosis in Serum During Cancer Therapy
Stig Linder, Professor, Karolinska Institute
Release of different molecular forms of cytokeratin-18 (caspase-cleaved and total CK18) from dying tumour cells can be used to measure tumour cell death modes in vitro and in vivo. Data suggests that CK18 serum biomarkers may be useful for early prediction of the response to anthracyclin-based therapy in breast cancer. |
|
16:20 |
Proteomic Characterisation of Tumoural Markers Correlated with ErbB2/HER2 Over-Expression and Metastasis in Breast Cancer
John Timms, Group Leader, UCL
Work aimed to identify protein markers of ErbB2-dependent and metastatic breast cancer using proteomics. IHC staining of tissue microarrays was used to validate results and RNAi-dependent gene silencing was used to examine the role of candidate markers in determining invasiveness. |
|
16:50 |
Close of Conference | |